dc.contributor.author | Çakan, Burçin | |
dc.contributor.author | Açıkgöz, Özgür | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Demir, Tarık | |
dc.contributor.author | Öven, Bala Başak | |
dc.contributor.author | Hamdard, Jamshid | |
dc.contributor.author | Olmuşçelik, Oktay | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Şeker, Mesut | |
dc.contributor.author | Yıldız, Özcan | |
dc.date.accessioned | 2021-11-30T06:55:13Z | |
dc.date.available | 2021-11-30T06:55:13Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Çakan, B., Açıkgöz, Ö., Bilici, A., Demir, T., Öven, B. B., Hamdard, J. ... Yıldız, Ö. (2021). Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. Journal of B.U.ON., 26(5), 1908-1917. | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/8589 | |
dc.description.abstract | Purpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of 201 patients with de novo mCRC who received first line treatment were retrospectively analyzed. Clinicopathological features, treatment outcomes, the primary tumor surgery, metastasectomies/local therapies and survivals were evaluated in terms of both RAS mutation status and primary tumor sidedness. Results: Tumor localization showed 140 (69.7%) patients with left-sided and 61 (30.3%) with right-sided tumors. Median progression-free survival (PFS) and overall survival (OS) were significantly shorter in patients with right-sided tumor than those with left-sided tumors (10.1 vs 12.9 months, p=0.005; 25 vs 44.4 months, p=0.008, respectively). In addition,the median OS interval of patients receiving anti-VEGF containing regimen was better than those treated with anti-EGFR containing regimen (50.7 vs. 26.9 months, p=0.001). Multivariate analysis indicated that age (HR:0.41,p=0.045), primary tumor resection (HR:0.41,p=0.037) and primary tumor localization (HR:0.38,p=0.021) for PFS and age (HR:0.39, p=0.09), the presence of BRAF mutation (HR:0.59,p=0.019) and the type of targeted therapy (HR:3.16,p=0.025) for OS were independent prognostic factors. Conclusions: Our results showed that primary tumor location is a prognostic factor in mCRC patients regardless of RAS status. Primary tumor location before treatment decision may be a simple indicator predicting survival and in choosing targeted agent. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Zerbinis Publications | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Anti-EGFR Therapy | en_US |
dc.subject | Anti-VEGF Therapy | en_US |
dc.subject | Colorectal Cancer | en_US |
dc.subject | RAS Mutation | en_US |
dc.subject | Tumor Sidedness | en_US |
dc.title | Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of B.U.ON. | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-2715-4002 | en_US |
dc.authorid | 0000-0002-5823-1704 | en_US |
dc.authorid | 0000-0002-9815-1848 | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.identifier.volume | 26 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 1908 | en_US |
dc.identifier.endpage | 1917 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopusquality | Q3 | en_US |